HPSE and plasma cell myeloma: A recent study also determines heparanase as a potential target for SARS-CoV-2 for a heparanase inhibitor Roneparstat (in phase I clinical trial for multiple myeloma therapy) reduces viral infection (Xiang et al., 2022).